SEC Form 8-K Summary
Registrant: Blue Water Vaccines Inc. (Nasdaq: BWV), although the request metadata identifies Onconetix, Inc.; the filing text concerns Blue Water Vaccines Inc.
Reporting date: February 17, 2022; filed February 24, 2022. The offering closed February 23, 2022.
Business Context and Transaction
The company entered into an underwriting agreement for a firm-commitment public offering of common stock. The offering was registered on Form S-1, which became effective February 11, 2022.
Key Financial and Capital Markets Metrics
| Item | Amount or Terms |
|---|---|
| Common shares sold | 2,222,222 |
| Offering price | $9.00 per share |
| Gross proceeds | Approximately $20.0 million, based on the stated share count and offering price |
| Net proceeds | Approximately $17.8 million after underwriting discounts, fees, expenses, and estimated offering costs |
| Representative’s warrants | Warrants to purchase 111,111 shares at $10.35 per share |
| Warrant term | February 23, 2022 through February 11, 2027 |
| Preferred-stock conversion | All outstanding Series Seed preferred shares and accrued dividends converted into 5,626,365 common shares |
The filing does not provide revenue, profit, cash-flow, margin, debt, liquidity-balance, or operating guidance metrics.
Material Changes Versus the Prior Period
- The company completed a public equity offering and received approximately $17.8 million in net proceeds.
- Outstanding Series Seed preferred stock and accrued dividends converted into 5,626,365 common shares, materially increasing common shares outstanding.
- The company issued warrants to the underwriter that could result in additional future dilution.
- The right-of-first-refusal and co-sale agreement and the voting agreement terminated in connection with the offering.
- The company adopted an amended and restated certificate of incorporation and amended and restated bylaws.
- John Rice resigned from the board, and James Sapirstein was appointed as a director. The filing states that Mr. Rice’s departure was not due to disagreement with management or the board.
Outlook, Risks, Contingencies, and Unusual Items
- The company agreed not to offer, sell, or issue securities for 12 months after the offering closing, subject to specified exempt issuances.
- The representative’s warrants include demand and piggyback registration rights and customary anti-dilution provisions.
- The equity offering and preferred-stock conversion create potential dilution for existing and future shareholders.
- The filing does not specify the intended uses of the net proceeds or provide financial guidance.
- The underwriting agreement contains customary representations, warranties, and other closing provisions.
Key Facts for Investors to Verify
- Confirm that the filing applies to Blue Water Vaccines Inc., not Onconetix, Inc.
- Review the amended and restated certificate of incorporation and bylaws for changes to shareholder and governance rights.
- Verify the post-offering common-share count, including the 2,222,222 newly issued shares and 5,626,365 shares issued upon preferred-stock conversion.
- Assess potential dilution from the 111,111 representative’s warrants and any other outstanding securities.
- Review the company’s subsequent filings for the use of the approximately $17.8 million in net proceeds, liquidity, operating results, and financing needs.